scholarly journals [Metabolic effects of Ramadan fasting on type 2 diabetes]

2003 ◽  
Vol 9 (5-6) ◽  
pp. 1099-1108
Author(s):  
R. Bouguerra ◽  
A. Belkadhi ◽  
J. Jabrane ◽  
J. Hamzaoui ◽  
C. Maatki ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Nous Avons ◽  
Metabolic Effects ◽  
Ramadan Fasting ◽  
Consommation Alimentaire

Nous avons analysé les effets métaboliques, en particulier les variations du cholestérol HDL, du jeûne du mois de ramadan chez 25 diabétiques de type 2 bien équilibrés traités par le régime ou les antidiabétiques oraux. Nos patients ont été évalués trois semaines avant le ramadan, durant la quatrième semaine du mois de ramadan et trois semaines aprés le mois de ramadan. Cette évaluation a comporté une enquête clinique, une enquête nutritionnelle et des analyses biologiques. Le jeûne du mois de ramadan n’a pas eu d’influence sur le poids, la tension artérielle, la glycémie, la fructosamine et l’hémoglobine A1c. Nous avons trouvé une relation négative entre les variations du cholestérol HDL et la consommation alimentaire de cholestérol. Le cholestérol HDL a augmenté de 13 % à la fin du jeûne et de 23 % trois semaines après la fin du jeûne chez les diabétiques ayant eu une consommation alimentaire de cholestérol inférieure à 400 mg/j

Metformin: Up to Date

2020 ◽  
Vol 20 (2) ◽  
pp. 172-181 ◽  
Author(s):  
Silvia Sciannimanico ◽  
Franco Grimaldi ◽  
Fabio Vescini ◽  
Giovanni De Pergola ◽  
Massimo Iacoviello ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Current Literature ◽  
Weight Control ◽  
Low Cost ◽  
Hepatic Glucose Production ◽  
Metabolic Effects ◽  
Hypoglycemic Agents ◽  
Positive Effects ◽  
Mesh Terms

Background: Metformin is an oral hypoglycemic agent extensively used as first-line therapy for type 2 diabetes. It improves hyperglycemia by suppressing hepatic glucose production and increasing glucose uptake in muscles. Metformin improves insulin sensitivity and shows a beneficial effect on weight control. Besides its metabolic positive effects, Metformin has direct effects on inflammation and can have immunomodulatory and antineoplastic properties. Aim: The aim of this narrative review was to summarize the up-to-date evidence from the current literature about the metabolic and non-metabolic effects of Metformin. Methods: We reviewed the current literature dealing with different effects and properties of Metformin and current recommendations about the use of this drug. We identified keywords and MeSH terms in Pubmed and the terms Metformin and type 2 diabetes, type 1 diabetes, pregnancy, heart failure, PCOS, etc, were searched, selecting only significant original articles and review in English, in particular of the last five years. Conclusion: Even if many new effective hypoglycemic agents have been launched in the market in the last few years, Metformin would always keep a place in the treatment of type 2 diabetes and its comorbidities because of its multiple positive effects and low cost.

scholarly journals Metabolic effects of bariatric surgery on patients with type 2 diabetes: a population-based study

2021 ◽  
Author(s):  
Erman O. Akpinar ◽  
Ronald S.L. Liem ◽  
Simon W. Nienhuijs ◽  
Jan Willem M. Greve ◽  
Perla J. Marang-van de Mheen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Bariatric Surgery ◽  
Population Based ◽  
Metabolic Effects ◽  
Population Based Study

Orlistat in Obese Patients with Type 2 Diabetes: A Retrospective Assessment of Weight Loss and Metabolic Effects

2004 ◽  
Vol 39 (1) ◽  
pp. 37-42 ◽  
Author(s):  
Edward C. Allie ◽  
Michael P. Kane ◽  
Robert S. Busch ◽  
Gary Bakst ◽  
Robert A. Hamilton
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Metabolic Effects ◽  
Obese Patients ◽  
Retrospective Assessment

scholarly journals Impact of Ramadan Diurnal Intermittent Fasting on Hypoglycemic Events in Patients With Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials and Observational Studies

2021 ◽  
Vol 12 ◽  
Author(s):  
Dana Abdelrahim ◽  
MoezAlIslam E. Faris ◽  
Mohamed Hassanein ◽  
Ayman Z. Shakir ◽  
Ayesha M. Yusuf ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Randomized Controlled Trials ◽  
Observational Studies ◽  
Dietary Behaviors ◽  
Controlled Trials ◽  
Ramadan Fasting ◽  
Randomized Controlled ◽  
The Impact

Ramadan is the 9th month of the lunar calendar during which Muslims abstain from food and drink between dawn and sunset for 30 consecutive days. Ramadan fasting is observed by all healthy Muslim adults, as well many Muslims with type 2 diabetes (T2DM). Hypoglycemic events (HE) are a serious complication associated with diabetes management and are associated with increased cardiovascular disease risk. Conflicting results have been reported concerning the incidence of HE among people with T2DM observing Ramadan fasting. This review summarizes available scientific evidence on the occurrence of HE and the effects of different moderators on the incidence of HE among patients with T2DM during Ramadan. We conducted a systematic review of available observational studies and randomized controlled trials (RCTs) for patients with T2DM who fasted during Ramadan, with HE as the primary outcome. Ten databases were searched for relevant studies from inception until October 31, 2020. In total, 68 studies (35 RCTs and 33 observational studies) met the inclusion criteria. Non-sulfonylureas hypoglycemic medications showed superior effects in lowering the incidence of HE over sulfonylureas hypoglycemic medications. Variable moderators were associated with experiencing HE during Ramadan in both observational studies and RCTs, including sex, geographical location, body anthropometric indicators, season, dietary behaviors, fasting duration, time since diagnosis, and pre-fasting education. This comprehensive systematic review covered the largest number of observational and clinical studies investigating the impact of Ramadan on HE among patients with T2DM. The study highlights the significance of different moderators that influence the effect of Ramadan fasting on HE, including dietary behaviors, fasting time duration, sex, season, country, pre-fasting education, age, and time since diagnosis. The study also highlighted the impact of different hypoglycemic medications on HE and noted the superiority of non-sulfonylureas over sulfonylureas hypoglycemic medications in lowering the risk for hypoglycemia in people with T2DM during Ramadan fasting.

Sign in / Sign up

Export Citation Format

Share Document